Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Hypertension and retinal microvascular dysfunction: A cross-sectional and randomized controlled exercise trial
Third-party funded project
Project title Hypertension and retinal microvascular dysfunction: A cross-sectional and randomized controlled exercise trial
Principal Investigator(s) Streese, Lukas
Co-Investigator(s) Hanssen, Henner
Organisation / Research unit Departement Sport, Bewegung und Gesundheit / Präventive Sportmedizin (Hanssen)
Department Departement Sport, Bewegung und Gesundheit,
Departement Sport, Bewegung und Gesundheit / Präventive Sportmedizin (Hanssen)
Project start 01.01.2021
Probable end 30.06.2022
Status Completed
Abstract

Hypertension is a worldwide health care burden that affects the structure and function of the macro- and microcirculation. Non-invasive vascular biomarkers are essential to timely diagnose end-organ damage to improve CV risk stratification and medical decision making. The “Hypertension and retinal microvascular dysfunction” (HyperVasc) trial will investigate macro- and microvascular impairments in hypertensive patients and healthy controls to investigate hypertension-induced end-organ damage by using gold-standard methods as well as newly developed and unique retinal microvascular biomarkers. Additionally, this trial will investigate the reversible effects of an eight weeks supervised and walking based high-intensity exercise intervention on blood pressure as well as macro- and microvascular health, compared to a control group with standard physical activity recommendations. Secondary outcomes will be cardiorespiratory fitness, physical activity, microalbuminuria, hypertensive retinopathy, and classical cardiovascular risk marker. The results of the HyperVasc trial will improve the understanding of hypertension-induced vascular impairments and will push the development of non-invasive vascular biomarker to screen end-organ damage in general CV risk stratification.

Financed by University of Basel
   

MCSS v5.8 PRO. 0.404 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
18/05/2024